Alnylam Pharmaceuticals

World Rank (Jul-30-2023)
762
Market Cap (Jul-30-2023)
24.817 Billion USD
World Rank (Dec-25-2022)
578
Market Cap (Dec-25-2022)
29.268 Billion USD
World Rank (Jan-07-2022)
1,156
Market Cap (Jan-07-2022)
17.716 Billion USD
World Rank (Jan-01-2021)
1,185
Market Cap (Jan-01-2021)
15.100 Billion USD
Company Rank in Country in 2023
Company Rank in USA in July-2023 is 325
Annual Revenue in USD
1,037 Million USD
Annual Net Income in USD
-1,131 Million USD
Total Assets in USD
3,546 Million USD
Total Liabilities in USD
3,704 Million USD
Annual Results for Year ending in
Dec-2022 month
Headquarters State / City
Massachusetts
Headquarters Country
USA
Company Business
Healthcare
Pharmaceutical
HealthCare Products
Biopharmaceutical
Biotechnology
Stock Exchange
Nasdaq
Company Rank in Country in 2022
Company Rank in USA in 2022 is 481
Rank in Country (Jan-2021)
Company Rank in USA in 2021 is 467
Rank in Country (Jan-2020)
Rank in USA in 2020 is 463
Number of Employees
2,002
Employee Count as on Date
As on 2022
CEO:
John Maraganore
Yahoo
Yahoo @ Nasdaq
Wikipedia
Wikipedia
Company Website:
ALNYLAM PHARMACEUTICALS INC
About Company Business:

ALNYLAM PHARMACEUTICALS is Biopharmaceutical company with headquarters in Massachusetts, USA.ALNYLAM  leaders from the biopharmaceutical industry, bringing together their experiences of drug discovery, drug development, and commercialization.Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines.

ALNYLAM PHARMACEUTICALS was NEW CLINICAL PROGRAMS ADDED IN 2021 and 2.4 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT YEAR-END 2021.

As on 2022, ALNYLAM PHARMACEUTICALS has 2,002 employees.

ALNYLAM PHARMACEUTICALS annual revenue generated for period ending Dec-2022 was 1,037 million USD.

ALNYLAM PHARMACEUTICALS annual net loss generated for period ending Dec-2022 was -1,131 (Loss) million USD.

ALNYLAM PHARMACEUTICALS total number of employees in 2021 was 1,850 and 23 countries with Alnylam offices.

ALNYLAM PHARMACEUTICALS annual revenue generated for period ending Jun-2022 was 844 million USD.

ALNYLAM PHARMACEUTICALS annual net income generated for period ending Jun-2022 was -852 million USD.

 

 

IPO Year
2004
Founded Year
2002
Annual Results Summary:

ALNYLAM PHARMACEUTICALS - Annual Result Summary - in Million USD

Year Ending: Total Revenue Gross Profit Operating Income Net Income
Dec-2022 1,037 868 -785 (Loss) -1,131 (Loss)
Dec-2021 844 704 -708 (Loss) -852 (Loss)
Dec-2020 493 414 (828.4) (Loss) (858.3) (Loss)
Dec-2019 219 194 (939.4) (Loss) (886.1) (Loss)
Dec-2018 75 73 (814.7) (Loss) (761.5) (Loss)
Dec-2017 90 90 (500.1) (Loss) (490.9) (Loss)
Quarterly Results Summary:

ALNYLAM PHARMACEUTICALS - Quarterly Results Summary - in Million USD

Quarterly Ending:

 Total Revenue Operating-Income Net Income
Jun-2023 318 -229 (Loss) -276 (Loss)
Mar-2023 319 -149 (Loss) -174 (Loss)
Dec-2022 335 -188 (Loss) -207 (Loss)
Sep-2022 264 -258 (Loss) -405.9 (Loss)
Jun-2022 224 -191.6 (Loss) -277.4 (Loss)
Mar-2022 213 -146.7 (Loss) -240 (Loss)
Dec-2021 258 -194.5 (Loss) -258 (Loss)
Sep-2021 187 -181.6 (Loss) -204.5 (Loss)
Institutional Investors

Top 30 Institutional Holder Names in ALNYLAM PHARMACEUTICALS  as on SEP-30-2023

RANK INSTITUTION  NAME DATE SHARES HELD CHANGE (SHARES) CHANGE (%) VALUE (IN 1,000S)
1 CAPITAL WORLD INVESTORS 09/30/2023 1,65,29,308 31,757 0.19% $2,706,344
2 VANGUARD GROUP INC 09/30/2023 1,16,56,831 30,608 0.26% $1,908,573
3 FMR LLC 09/30/2023 1,12,81,406 -12,11,094 -9.70% $1,847,105
4 BLACKROCK INC. 09/30/2023 83,93,004 6,842 0.08% $1,374,187
5 BAILLIE GIFFORD & CO 09/30/2023 81,63,139 -2,29,077 -2.73% $1,336,551
6 WELLINGTON MANAGEMENT GROUP LLP 09/30/2023 64,31,814 3,64,021 6.00% $1,053,081
7 PRICE T ROWE ASSOCIATES INC /MD/ 09/30/2023 39,25,004 39,468 1.02% $642,641
8 DODGE & COX 09/30/2023 37,47,155 -42,370 -1.12% $613,522
9 T. ROWE PRICE INVESTMENT MANAGEMENT, INC. 09/30/2023 33,98,859 1,61,235 4.98% $556,495
10 CAPITAL INTERNATIONAL INVESTORS 09/30/2023 30,97,843 2,17,200 7.54% $507,210
11 JPMORGAN CHASE & CO 09/30/2023 30,86,846 -46,128 -1.47% $505,409
12 STATE STREET CORP 09/30/2023 28,99,513 7,266 0.25% $474,737
13 CAPITAL RESEARCH GLOBAL INVESTORS 09/30/2023 27,83,843 4,29,082 18.22% $455,799
14 GEODE CAPITAL MANAGEMENT, LLC 09/30/2023 18,39,505 37,483 2.08% $301,182
15 RTW INVESTMENTS, LP 09/30/2023 16,83,362 0 0% $275,617
16 MORGAN STANLEY 09/30/2023 12,09,383 -6,71,423 -35.70% $198,012
17 NORGES BANK 12/31/2022 10,12,846 -2,05,338 -16.86% $165,833
18 AVORO CAPITAL ADVISORS LLC 09/30/2023 10,11,111 -93,889 -8.50% $165,549
19 BELLEVUE GROUP AG 09/30/2023 8,94,345 -5,305 -0.59% $146,431
20 BANK OF NEW YORK MELLON CORP 09/30/2023 8,37,084 61,488 7.93% $137,056
21 NORTHERN TRUST CORP 09/30/2023 7,97,700 25,230 3.27% $130,607
22 LEGAL & GENERAL GROUP PLC 09/30/2023 7,94,671 -3,718 -0.47% $130,111
23 PICTET ASSET MANAGEMENT HOLDING SA 09/30/2023 7,90,755 7,90,755 New $129,470
24 UBS ASSET MANAGEMENT AMERICAS INC 09/30/2023 7,74,476 1,00,598 14.93% $126,805
25 AMERIPRISE FINANCIAL INC 09/30/2023 7,06,200 80,862 12.93% $115,626
26 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 09/30/2023 6,88,228 15,831 2.35% $112,684
27 PICTET ASSET MANAGEMENT SA 06/30/2023 6,48,546 44,471 7.36% $106,186
28 LOOMIS SAYLES & CO L P 09/30/2023 6,25,401 -19,742 -3.06% $102,397
29 AMUNDI 09/30/2023 6,14,359 -60,409 -8.95% $100,589
30 GILDER GAGNON HOWE & CO LLC 09/30/2023 5,94,979 -3,717 -0.62% $97,416

Share it on Social Media